Gail Frances  Mcintyre net worth and biography

Gail Mcintyre Biography and Net Worth

CEO of Aravive
Gail McIntyre, Ph.D., is a seasoned biopharma executive with more than 25 years of experience. Dr. McIntyre has been Aravive’s Chief Executive Officer since April 2020. Previously she was Chief Scientific Officer since February 2019 and has been with the company since August 2016 as head of R&D. Having brought multiple drugs to market, Dr. McIntyre’s drug development expertise spans multiple disciplines and therapeutic areas as well as strategic business development, licensing and M&A. Previously, Dr. McIntyre served as a principal at IntelliDev Consulting, LLC providing consulting services to several biotechnology companies for three years including heading development of a cancer company from Jan 2014 to Jan 2016. Prior to that, Dr. McIntyre held the position of Senior Vice President of research at Furiex Pharmaceuticals, Inc. and previously served as Head of Pharmaceutical Product Development (PPD) LLC’s compound partnering business. At both Furiex and PPD, she strategized and managed all preclinical and clinical activities for drug development programs and was responsible for identification of new partnering opportunities and technical due diligence for both in-licensing opportunities and new business acquisitions. She led the partnering and the in-licensing of Nesina™ from Syrrx, Inc. at preclinical stage and the licensing to Takeda at Phase 2. She was instrumental to the licensing of Priligy™ to what is currently Johnson & Johnson and then The Menarini Group. She played a pivotal role in the $1.1B acquisition of Allergan in 2014 and successfully negotiated with Controlled Substances Staff on scheduling for Viberzi®. Dr. McIntyre has authored more than 30 regulatory submissions. Her experience covers multiple therapeutic areas such as oncology (including immune-oncology), infectious diseases, central nervous system, gastrointestinal, and metabolic/endocrine as well as various therapeutic modalities including small molecules, treatment vaccines, antibodies, immunoconjugates and peptide mimetics. Dr. McIntyre is a board-certified toxicologist and board certified in Clinical Pathology (hematology and clinical chemistry) by the American Society of Clinical Pathology. Dr. McIntyre received her B.A. in Biology from Merrimack College. She earned M.S. and Ph.D. degrees in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

What is Gail Frances Mcintyre's net worth?

The estimated net worth of Gail Frances Mcintyre is at least $7,652.76 as of June 29th, 2021. Dr. Mcintyre owns 190,842 shares of Aravive stock worth more than $7,653 as of March 29th. This net worth evaluation does not reflect any other assets that Dr. Mcintyre may own. Learn More about Gail Frances Mcintyre's net worth.

How do I contact Gail Frances Mcintyre?

The corporate mailing address for Dr. Mcintyre and other Aravive executives is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. Aravive can also be reached via phone at (936) 355-1910 and via email at [email protected]. Learn More on Gail Frances Mcintyre's contact information.

Has Gail Frances Mcintyre been buying or selling shares of Aravive?

Gail Frances Mcintyre has not been actively trading shares of Aravive in the last ninety days. Most recently, on Tuesday, June 29th, Gail Frances Mcintyre bought 1,000 shares of Aravive stock. The stock was acquired at an average cost of $5.34 per share, with a total value of $5,340.00. Following the completion of the transaction, the chief executive officer now directly owns 190,842 shares of the company's stock, valued at $1,019,096.28. Learn More on Gail Frances Mcintyre's trading history.

Who are Aravive's active insiders?

Aravive's insider roster includes Amato Giaccia (Director), and Gail Mcintyre (CEO). Learn More on Aravive's active insiders.

Gail Frances Mcintyre Insider Trading History at Aravive

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2021Buy1,000$5.34$5,340.00190,842View SEC Filing Icon  
See Full Table

Gail Frances Mcintyre Buying and Selling Activity at Aravive

This chart shows Gail Frances Mcintyre's buying and selling at Aravive by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aravive Company Overview

Aravive logo
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Read More

Today's Range

Now: $0.04
Low: $0.04
High: $0.04

50 Day Range

MA: $0.04
Low: $0.04
High: $0.05

2 Week Range

Now: $0.04
Low: $0.04
High: $2.46

Volume

N/A

Average Volume

N/A

Market Capitalization

$2.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11